Create a narrative

BioCryst Pharmaceuticals Community

NasdaqGS:BCRX Community

1 Narratives written by author
0 Comments on narratives written by author
24 Fair Values set on narratives written by author

BioCryst Pharmaceuticals

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 11 Analysts

Expanding Rare Disease Pipeline Will Open New Markets

Key Takeaways Sustained revenue and profit growth are driven by successful ORLADEYO performance, new indications, and broader rare disease market expansion. Enhanced financial flexibility and a strong pipeline position BioCryst for strategic growth through M&A, new product launches, and operational leverage.

US$16.73

FV

49.0% undervalued

11.73%

Revenue growth p.a.

0

0

14

6 days ago